Document is current
Any future updates will be listed below
-
Authors
Hu, Qinqin https://orcid.org/0000-0001-5726-9279
Tong, Zongxuan
Yalikong, Ayimukedisi https://orcid.org/0000-0002-7328-8354
Ge, Li-Ping https://orcid.org/0000-0002-3578-0073
Shi, Qiang
Du, Xinyu
Wang, Pu https://orcid.org/0000-0002-9185-1913
Liu, Xi-Yu
Zhan, Wuqiang
Gao, Xia https://orcid.org/0000-0002-7573-9382
Sun, Di
Fu, Tong
Ye, Dan
Fan, Chunhai https://orcid.org/0000-0002-7171-7338
Liu, Jie
Zhong, Yun-Shi https://orcid.org/0000-0001-8382-3747
Jiang, Yi-Zhou https://orcid.org/0000-0003-3699-2630
Gu, Hongzhou https://orcid.org/0000-0001-5058-4815
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 17 August 2023
First Online: 14 September 2023
Competing interests
: Three Chinese patents have been filed, with a status of initiative for examination as to substance. Q.H., Z.T., L.-P.G., X.-Y.L., T.F., Y.-Z.J. and H.G. declare the following competing interests: patent no. CN202110364792.0 was applied for by Fudan University Shanghai Cancer Center, covering the identified DNAzyme probes that selectively sense MDA-MB-231 cells in this study; and patent no. CN202110361337.5 was also applied for by Fudan University Shanghai Cancer Center, covering the method to identify the potential biomarker (APOL6) of breast cancer based on the DNAzyme probes in this study. Z.T., A.Y., Q.S., D.S., Y.-S.Z. and H.G. declare the following competing interests: patent no. CN202111198079.X was applied for by Zhongshan Hospital, Fudan University, covering the findings of the DNAzyme probes that selectively sense LGIN/HGIN specimens and the probes’ utility in biomarker discovery in this study. X.D., P.W., W.Z., X.G., D.Y., C.F. and J.L. declare no competing interests.
